版本:
中国

BRIEF-Biogen says Spinraza approved in EU as first treatment for SMA

June 1 Biogen Inc:

* Spinraza (nusinersen) approved in the European Union as first treatment for spinal muscular atrophy

* Biogen - ‍approval was also supported by open-label data in pre-symptomatic and symptomatic individuals with, or likely to develop, types 1, 2 and 3 SMA​

* Biogen Inc - ‍timing of Spinraza availability in eu will vary by country, per local reimbursement and access pathways​

* Biogen Inc - ‍Biogen has been working with health systems and government agencies across EU to help patients secure access to Spinraza​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐